


Supplementary Materials: Formulation and Biological Evaluation of Mesoporous Silica Nanoparticles Loaded with Combinations of Sortase A Inhibitors and Antimicrobial Peptides

Sitah Alharthi, Zyta M. Ziora, Taskeen Janjua, Amirali Popat, Peter M. Moyle

Table S1. The concentrations of the sortase A inhibitor (SrtAIs; TC, CUR, QC, and BR)-loaded MCM-41 and MCM-41-PO₃⁻ MSNs, AMPs (PEX, INDO, and MASTO), and their combinations used in the cell viability study. Red values are the MICs of each compound.

| Compound | Concentrations ($\mu\text{g/mL}$) | | | | | |
|---|-------------------------------------|-------------|-------------|-------------|-------------|-------------|
| PEX | 50.0 | 25.0 | 12.5 | 6.25 | 3.13 | 1.56 |
| INDO | 150 | 75.0 | 37.5 | 18.8 | 9.38 | 4.69 |
| MASTO | 25.0 | 12.5 | 6.26 | 3.13 | 1.57 | 0.78 |
| TC MCM-41 | 1000 | 500 | 250 | 125 | 62.5 | 31.3 |
| CUR MCM-41 | 500 | 250 | 125 | 62.5 | 31.3 | 15.6 |
| QC MCM-41 | 500 | 250 | 125 | 62.5 | 31.3 | 15.6 |
| BR MCM-41 | 1000 | 500 | 250 | 125 | 62.5 | 31.3 |
| TC MCM-41-PO ₃ ⁻ | 500 | 250 | 125 | 62.5 | 31.3 | 15.6 |
| CUR MCM-41-PO ₃ ⁻ | 250 | 125 | 62.5 | 31.3 | 15.6 | 7.81 |
| QC MCM-41-PO ₃ ⁻ | 500 | 250 | 125 | 31.3 | 31.3 | 15.6 |
| BR MCM-41-PO ₃ ⁻ | 500 | 250 | 125 | 62.5 | 31.3 | 15.6 |
| PEX + TC MCM-41 | 12.5 + 125 | 6.25 + 62.5 | 3.13 + 31.3 | 1.56 + 15.6 | 0.78 + 7.81 | 0.39 + 3.91 |
| PEX + BR MCM-41 | 12.5 + 62.5 | 6.25 + 31.3 | 3.13 + 15.6 | 1.56 + 7.81 | 0.79 + 3.91 | 0.39 + 1.95 |
| INDO + QC MCM-41 | 37.5 + 125 | 18.8 + 62.5 | 9.38 + 31.3 | 4.68 + 15.6 | 2.34 + 7.81 | 1.17 + 3.91 |
| MASTO + CUR MCM-41 | 25.0 + 62.5 | 12.5 + 31.3 | 6.25 + 15.6 | 3.13 + 7.81 | 1.56 + 3.91 | 0.78 + 1.95 |
| PEX + TC MCM-41-PO ₃ ⁻ | 12.5 + 62.5 | 6.25 + 31.3 | 3.13 + 15.6 | 1.56 + 7.81 | 0.79 + 3.91 | 0.39 + 1.95 |
| PEX + BR MCM-41-PO ₃ ⁻ | 12.5 + 62.5 | 6.25 + 31.3 | 3.13 + 15.6 | 1.56 + 7.81 | 0.79 + 3.91 | 0.39 + 1.95 |
| INDO + QC MCM-41-PO ₃ ⁻ | 37.5 + 125 | 18.8 + 62.5 | 9.38 + 31.3 | 4.68 + 15.6 | 2.34 + 7.81 | 1.17 + 3.91 |

MCM-41



MCM-41- PO_3^-




Figure S1. Size, polydispersity index (PDI), intensity mean, and zeta potential of MCM-41 and MCM-41 PO_3^- MSNs.




Figure S2. N_2 -physisorption isothermal analysis and pore size distribution of SrtAI-loaded and non-loaded MCM-41 and MCM-41- PO_3^- MSNs.





Figure S3. (i) Wide and (ii) narrow RP-HPLC gradients and ESI-MS data for purified PEX, INDO, and MASTO AMPs.






Figure S5. Fractional inhibitory concentration (FIC) index of TC MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *S. aureus* ATCC25923 using checkerboard assay.




Figure S6. Fractional inhibitory concentration (FIC) index of TC MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against MRSA ATCC43300 using checkerboard assay.




Figure S7. Fractional inhibitory concentration (FIC) index of TC MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *E. coli* ATCC25922 using checkerboard assay.




Figure S8. Fractional inhibitory concentration (FIC) index of TC MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *P. aeruginosa* ATCC27853 using checkerboard assay.




Figure S9. Fractional inhibitory concentration (FIC) index of CUR MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *S. aureus* ATCC25923 using checkerboard assay.




Figure S10. Fractional inhibitory concentration (FIC) index of CUR MCM-41 and MCM-41-PO₃⁻ in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *MRS*A ATCC43300 using checkerboard assay.




Figure S11. Fractional inhibitory concentration (FIC) index of CUR MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *E. coli* ATCC25922 using checkerboard assay.




Figure S12. Fractional inhibitory concentration (FIC) index of CUR MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *P. aeruginosa* ATCC27853 using checkerboard assay.




Figure S13. Fractional inhibitory concentration (FIC) index of QC MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *S. aureus* ATCC25923 using checkerboard assay.




Figure S14. Fractional inhibitory concentration (FIC) index of QC MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against MRSA ATCC43300 using checkerboard assay.




Figure S15. Fractional inhibitory concentration (FIC) index of QC MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *E. coli* ATCC25922 using checkerboard assay.




Figure S16. Fractional inhibitory concentration (FIC) index of QC MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *P. aeruginosa* ATCC27853 using checkerboard assay.




Figure S17. Fractional inhibitory concentration (FIC) index of BR MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against MRSA ATCC43300 using checkerboard assay.




Figure S18. Fractional inhibitory concentration (FIC) index of BR MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *E. coli* ATCC 25922 using checkerboard assay.




Figure S19. Fractional inhibitory concentration (FIC) index of BR MCM-41 and MCM-41- PO_3^- in combination with antimicrobial peptides (AMPs; PEX, INDO, and MASTO) against *P. aeruginosa* ATCC27853 using checkerboard assay.




Figure S20. Effects of PEX, INDO, or MASTO on HEK-293 cell viability following 24 h incubation. Statistical analyses were performed using one-way ANOVA followed by Tukey's post-hoc test. No statistically significant differences were found ($p > 0.05$). Data is expressed as mean \pm SD ($n = 3$).




Figure S21. Fourier-transform infrared spectroscopy (FTIR) spectrum of the sortase A inhibitors (SrtAIs, TC, CUR, QC, and BR) alone and loaded into MCM-41 and MCM-41-PO₃⁻, and their physical mixture with MCM-41 and MCM-41-PO₃⁻.